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Abstract 
Background: Antigenicity of HIV-1 envelope proteins (Envs) of both lab-adapted and primary isolates expressed 
on the cell surface rarely match with in vitro neutralization of viruses, pseudo-typed with corresponding Envs. Often, 
both neutralizing and non-neutralizing antibodies bind to Envs expressed on the cell membrane. This could be due 
to the lack of efficient cleavage of Env expressed on the cell surface. Naturally occurring, efficiently cleaved Envs with 
appropriate antigenic properties are relatively rare. Given viral diversity it is essential to increase the pool of candidate 
Envs suitable for immunogen design. Previously, it has been reported that JRFL Env is the only clade B Env, which is 
efficiently cleaved on the cell surface and retains desirable antigenic properties. JRCSF is a clade B Env isolated from 
the same patient as JRFL. JRCSF Env has not been explored aggressively for designing immunogen as the binding 
characteristics of JRCSF Env to broadly neutralizing antibodies on the cell surface and its cleavage status are unknown.
Results: Although JRCSF preferentially binds to most of the other gp120-directed neutralizing antibodies and cleav-
age dependent antibody, PGT151 efficiently, it binds poorly to CD4-binding-site-directed (CD4-bs-directed) neu-
tralizing antibodies on cell surface. Membrane bound form of modified JRCSF Env containing the N197D mutation 
binds to CD4-bs-directed neutralizing antibodies better than JRFL, without debilitating its ability to bind quaternary 
epitope-directed neutralizing antibodies or exposing the CD4i antibody epitopes. In comparison to JRFL (E168K), 
JRCSF Env binds more efficiently to PG9/PGT145 class of V1/V2-directed conformational antibodies. Biochemical, cell 
surface staining and gp120 shedding experiments suggest that JRCSF is efficiently cleaved on the cell surface.
Conclusions: Binding of JRCSF Env expressed on cell surface to the various HIV-1 Env-directed antibodies has not 
been reported earlier. Here, for the first time, we report that compared to JRFL, JRCSF displays epitopes for a larger 
number of broadly neutralizing antibodies and is also efficiently cleaved when expressed on the cell surface. Thus, 
considering the diversity of viral Envs and the discovery of conformation dependent glycan-directed antibodies in 
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Background
In the past decade, one of the major strategies to develop 
a vaccine for HIV-1 has focused on activating the 
humoral immune response against genetically variable 
envelope glycoprotein (Env) to elicit broadly neutraliz-
ing antibodies (bNAbs) [1–4]. The Env mediates entry of 
the virion into target cells, undergoing conformational 
changes after engaging the primary receptor, CD4, and 
then binding to the co-receptor, usually CCR5; which 
ultimately leads to virus-to-cell membrane fusion and 
entry of virus into target cells [5–18]. Much has been 
learned from bNAbs binding and characterization studies 
on Env. For example, some of these bNAbs are depend-
ent on the trimeric conformation of Env and binding of 
one such recently isolated bNAb, PGT151 is cleavage 
dependent [19, 20]. These studies provide insights to help 
guide immunogen design to elicit such bNAbs; the major 
challenge currently impeding HIV vaccine development.
The current paradigm is that an important starting 
point for immunogen design is that it should mimic the 
native Env as present on the virus, since the functional, 
trimeric Env spikes selectively resist binding by all but 
the most precisely targeted NAbs [21, 22]. The non-cova-
lently linked trimeric form of the Envs are arranged on 
the membrane after the glycoprotein undergoes matu-
ration wherein the gp160 precursor is proteolytically 
cleaved by cellular enzymes belonging to the furin family 
into the gp120 (SU) and gp41 (TM) subunits [13].
Several reports have demonstrated that the efficient 
cleavage of gp160 is a prerequisite for preferential bind-
ing to neutralizing (NAbs) over non-neutralizing anti-
bodies (non-NAbs) on the cell surface [21, 23, 24]. 
Furthermore, the gp120-gp41 interaction is labile mak-
ing it difficult to develop soluble form of Env proteins 
that are metastable but retains a trimeric, native-like 
conformation. This problem has been circumvented by 
generating SOSIP versions (containing A501C, T605C, 
I559P mutations in BG505) of the cleaved, C-terminus 
truncated Env glycoprotein to aa664 and purifying the 
trimeric form [25]. Purified BG505SOSIP.664 (MPER 
deleted and contains the T332N substitution) forms a 
cleaved, trimeric, native-like Env protein that binds pref-
erentially to bNAbs but generally not to non-NAbs [21, 
25]. Recently, similar versions of JRFL, B41 (clade B) and 
16055 (clade C) have been generated, purified and dem-
onstrated similar properties [22, 26]. This current vaccine 
approach generally elicits autologous tier 2 nAbs, but not 
bNAbs [27], indicating that additional modifications to 
the immunogen and/or immunization strategy will be 
needed for induction of bNAbs
The cleaved, native, trimeric form of Env immunogen 
can be realized through DNA vaccination as well. DNA 
prime-protein boost vaccination strategy, including 
HIV-1 Env, has also been used in several clinical trials 
e.g. RV144. Studies have also shown that DNA prime-
soluble protein boost regimens frequently elicit qualita-
tively better NAbs compared to protein-only regimens 
[28–30]. This could be due to the expression of efficiently 
cleaved Env after DNA vaccination. However, naturally 
occurring, efficiently cleaved Envs that have been identi-
fied are rare. The clade B Env, JRFL was identified as the 
first naturally cleaved Env on the cell surface [24] and we 
have recently found a clade C Env 4-2.J41 from India that 
is also efficiently cleaved on the cell surface [23]. Using 
JRFL as a model system it has been demonstrated in non-
human primates (NHPs) that a DNA prime followed by 
non-native trimeric Env boost elicits low-titer neutrali-
zation activity against some difficult to neutralize Tier-2 
HIV-1 viruses [28]. In JRFL Env however, the epitopes for 
many of the recently discovered conformation-depend-
ent glycan-directed antibodies are not present [3].
It appears from recent reports that Envs like JRFL have 
a glycan-deficient gap that could elicit antibody directed 
to a conserved site to which access is usually modulated 
by a glycan for virus pseudotyped with other Envs [31]. 
Furthermore, in one study, with JRCSF gp120 DNA 
prime, followed by gp120 protein boost, NAbs against 
some tier 2 viruses were induced [32]. Therefore, in our 
search for additional Envs, which may be used for genetic 
vaccination and in developing soluble immunogens, we 
studied JRCSF, isolated from the cerebrospinal fluid of 
the same patient from which the well-studied clade B 
Env, JRFL (isolated from the frontal lobe) was isolated. 
Though there is ample information about the antigenic 
properties in relation to the efficiency of cleavage of JRFL 
Env [24], sufficient studies have not yet been done with 
JRCSF. Moreover, data related to the differential neutral-
izing sensitivity between JRFL and JRCSF to CD4-bs-
directed NAbs and other gp120-directed antibodies are 
in literature [3]. JRFL and JRCSF show 74 amino acid 
differences spread all over the gp160 polypeptide (Addi-
tional file 1: Figure 1).
Here, we show for the first time that JRCSF is an effi-
ciently cleaved Env when expressed on cell surface and 
HIV-1 infected individuals, an innately cleaved JRCSF Env as present on the viral membrane and displaying those 
distinct epitopes may be an important candidate for immunogen design.
Keywords: HIV, Envelope, Efficiently cleaved, Broadly neutralizing antibody binding, Immunogen design
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binds preferentially to most gp120-directed NAbs other 
than those directed against the CD4-bs. In addition, it 
does not bind to non-NAbs. The binding ability of JRCSF 
to CD4-bs-directed NAbs could be recovered without 
changing its native conformation through simple modi-
fication. JRCSF (N197D) appears to bind more efficiently 
to CD4-bs-directed NAbs than JRFL while JRCSF binds 
to PG9/PGT145 class of antibodies more efficiently than 
JRFL (E168K). As JRCSF Env is efficiently cleaved and can 
bind preferentially to all the different classes of quater-
nary epitope-dependent but glycan directed bNAbs when 
expressed on the cell surface, it may be better suited for 
use as a platform for designing immunogen due to its 
ability to bind to bNAbs targeting the trimer-specific V2 
“cap” while retaining its ability to bind CD4-bs-directed 
bNAbs through the N197D mutation. The implications of 
these findings are discussed.
Methods
DNA constructs, cell lines and antibodies
Swapping mutants of JRCSF in pSVIII-env plasmid back-
bone were constructed by replacing the corresponding 
regions of JRFL by PCR amplification using Pfu poly-
merase following manufacturer’s protocol. Briefly, these 
PCR amplified fragments were gel purified and used as 
primers along with JRCSF as template and PCR ampli-
fied with Phusion polymerase according to the manu-
facturer’s protocol. The reaction mixtures were digested 
with Dpn1, transformed into competent cells and plated 
onto LB-ampicillin plates. The swapped JRCSF variants 
were confirmed by sequencing of the plasmid DNA iso-
lated from unique colonies. For site-directed mutagen-
esis, mutagenic primers were designed according to the 
Quikchange site directed mutagenesis kit manual (Qia-
gen) and PCR was carried out with Phusion polymerase. 
The reaction mixtures were digested with Dpn1, trans-
formed into competent cells and plated onto LB-ampicil-
lin plates. The mutations were confirmed by sequencing 
of the plasmid DNA isolated from unique colonies. TZM-
bl and 293T cells were obtained from NIH AIDS Reagent 
Program and ATCC, respectively. They were maintained 
in DMEM (Dulbecco’s modified Eagle medium) contain-
ing 10% HIFBS (heat inactivated fetal bovine serum), 
20 mM l-glutamine, 100 U/ml penicillin, and 100 μg/ml 
streptomycin. Broadly neutralizing antibodies (VRC01, 
b12, PGT121, PGT145, PGT151, PG9, PG16, 10E8, 
2G12) and non-neutralizing antibodies (F105, b6, 39F, 
and 17b) were obtained from the IAVI Neutralizing Anti-
body Center (NAC) at TSRI, La Jolla, California.
FACS‑based cell surface expression assay
FACS-based cell surface expression assay was carried out 
as described previously [33]. It is to be noted here that 
we have used the full-length clones of both JRFL and 
JRCSF in all our studies. Briefly, 293T cells were tran-
siently transfected with pSVIII-Env plasmids express-
ing different forms of Env protein under the control of 
the HIV-1 LTR and pc-tat plasmid expressing Tat pro-
tein at the ratio of 20:1. 36–48 h post transfection, cells 
were harvested, washed three times with FACS buffer 1 
(DMEM + 10% HIFBS) and stained with varying concen-
trations of monoclonal antibodies (neutralizing and non-
neutralizing) for 1 h at room temperature (RT). The cells 
were washed three times with FACS buffer 1 and then 
stained with PE-conjugated goat anti-human secondary 
antibody (1:200 dilutions, Jackson ImmunoResearch) for 
1 h at RT. The cells were again washed three times with 
FACS buffer 2 (PBS +  10% HIFBS) and fixed with 0.5% 
paraformaldehyde. The stained cells were then analyzed 
in a FACS Canto analyzer (BD Biosciences) and data ana-
lyzed with FlowJo software (version 10.0.6, Tree Star Inc).
Plasma membrane fraction isolation, immunoprecipitation, 
gp120 shedding assays
Plasma membrane fractions of 293T cells transfected 
with different Envs were isolated using the Plasma Mem-
brane Protein Isolation kit (Abcam) following the manu-
facturer’s protocol. PM fractions were resuspended in 
lysis buffer (10  mM Tris–HCl (pH 8.0), 150  mM NaCl, 
1% Triton-X, 1  mM DTT and protease inhibitors) and 
immunoprecipitated (with rotation) O/N at 4  °C with 
bNAbs. Next day the mixture was incubated (with rota-
tion) for 1  h at 4  °C with Immobilized Protein G resins 
(G Biosciences) and washed three times with PBS + 1% 
Triton-X. Washed beads were analyzed by western blot 
analysis using HIVIG Ab.
CD4-induced shedding of gp120 was assayed as 
described previously [23]. Briefly, cells transfected with 
plasmids expressing JRCSF Env were harvested and 
washed with FACS buffer 2 and then incubated with or 
without 50 µg/ml sCD4-183 (NIH AIDS Reagent) for 1 h 
at 4  °C with intermittent mixing. Cells were centrifuged 
and the supernatant subjected to ELISA as described 
previously [23] except that mAb, 39F was used as the pri-
mary antibody (1:1000 dilution) and peroxidase-coupled 
goat anti-human IgG (Jackson ImmunoResearch, Cat No. 
109-036-008) was used as secondary antibody.
Results
Differential binding to CD4‑bs bNAbs by JRFL and JRCSF
Efficient binding to neutralizing antibodies and weak or 
no binding to non-neutralizing antibodies by Env on the 
cell surface can be used as a marker for determining the 
efficiency of cleavage of the Env gp160 to its constituent 
subunits [3, 23, 24]. It has been previously demonstrated 
that pseudoviruses prepared with either JRFL or JRCSF 
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Env are neutralized by CD4-bs neutralizing antibodies 
[3, 34]. However, JRFL pseudotyped viruses are neutral-
ized at least fivefold to tenfold more efficiently than JRCSF 
pseudotyped viruses by CD4-bs bNAbs (Table  1). In cell 
surface FACS-based staining assays, Walker et al. [3] had 
observed a differential binding of JRCSF and JRFL with the 
CD4-bs bNAb b12. In order to characterize JRCSF, we first 
determined its ability to bind to CD4-bs bNAbs b12 and 
VRC01 and the CD4-bs non-neutralizing Abs F105 and 
b6 by FACS-based cell surface staining assays (Fig. 1). We 
used binding to 2G12 as a marker for determining levels of 
expression. We observed that while JRFL binds efficiently 
to b12 and VRC01, JRCSF, in contrast, binds only margin-
ally to CD4-bs bNAbs on the cell surface (Fig. 1b, c). Both 
Envs bind poorly to the non-NAbs F105 and b6 (Fig. 1d, 
e) while they bind to a similar extent to 2G12 suggesting 
equivalent levels of expression (Fig.  1a). Taken together 
these studies suggest that JRCSF is defective in its ability to 
bind CD4-bs bNAbs as compared to JRFL. However, like 
JRFL, JRCSF binds CD4-bs-directed non-NAbs poorly.
JRCSF binds preferentially to neutralizing antibodies
It has been reported previously that naturally cleaved 
HIV-1 Envs, JRFL and 4-2.J41 when expressed on the cell 
surface, selectively binds to neutralizing antibodies [23, 
24, 33]. Uncleaved Envs can bind to both neutralizing 
and non-neutralizing antibodies [21, 23, 24, 33, 35]. The 
soluble, native-like trimers of BG505SOSIP.664 [25, 35, 
36] and some other soluble native trimeric proteins have 
been made following this principle [22, 37]. In order to 
investigate whether JRCSF demonstrates similar prop-
erties, we wanted to check the binding ability of JRCSF 
Env expressed on the cell surface to both neutralizing 
and non-neutralizing antibodies. To compare the bind-
ing ability of both bNAbs targeting diverse epitopes 
(via the trimer selective V2 “cap”, the V3 region and the 
MPER region) and non-neutralizing antibodies to JRFL 
and JRCSF Envs, a FACS-based cell surface antibody 
binding assay was carried out with different neutraliz-
ing and non-neutralizing antibodies over a range of anti-
body concentrations as indicated in Fig. 2. We observed 
that both JRFL and JRCSF bind to the glycan-dependent 
bNAb 2G12 with equal efficiency (Fig. 2a) suggesting that 
they are expressed at similar levels. They also bind to the 
cleavage-specific and trimer-dependent bNAb PGT151 
with equal efficiency (Fig.  2a). In addition, JRFL and 
JRCSF bind to V3 dependent conformational antibody, 
PGT121 and MPER targeted antibody, 10E8 to similar 
extent (Fig.  2c, e). As determined previously for JRFL 
with 2F5 and 4E10 [33], binding to these MPER-directed 
antibodies was relatively less efficient with JRCSF. On 
the other hand, in agreement with previous studies [3], 
while JRCSF binds efficiently to the V2 region targeted, 
glycan and quaternary structure-dependent antibodies 
PG9, PG16 (data not shown) and PGT145 (Fig. 2d), JRFL 
does not bind to these antibodies. Binding to this class 
of bNabs can be restored in JRFL by the E168K mutation 
[22]. Furthermore, while JRFL binds to the newly discov-
ered fusion peptide-directed bNAb, VRC34 efficiently, 
JRCSF binds to it only marginally on cell surface (Fig. 2b). 
In pseudovirus neutralization assay, VRC34 modestly 
neutralizes JRFL pseudotyped viruses with an IC50 value 
of 1.1  µg/ml, while the IC50 for JRCSF pseudotyped 
viruses is >10 µg/ml (Table 1) suggesting that in JRCSF, 
the epitope for VRC34 is either inaccessible or is not in 
the same conformation as in JRFL. We also compared 
the ability of JRFL and JRCSF to bind to non-neutralizing 
antibodies. JRFL and JRCSF bind only marginally and to 
a similar extent to the non-neutralizing antibodies, 39F, 
A32 and the CD4i antibody 17b (Fig.  2f–h). Thus, both 
JRFL and JRCSF bind preferentially to neutralizing anti-
bodies targeting the gp120-gp41 interface, V3 region 
as well as MPER epitopes. In contrast to JRFL, JRCSF 
binds to the quaternary structure-dependent V2 epitope-
targeted antibodies PG9, PG16 and PGT145 efficiently. 
Both Envs bind to non-neutralizing antibodies poorly. 
These findings with JRFL and JRCSF expressed on the cell 
surface are in agreement with pseudovirus neutraliza-
tion data (Table  1) performed in our laboratory (in this 
Table 1 Representative neutralization data of  JRFL 






mAb epitope mAb JRFL JRCSF






CD4i 17b − −






MPER 10E8 ++ ++
4E10 + +
2F5 + +
FP VRC34 + ±
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manuscript and data not shown) and also reported previ-
ously [3, 34, 38].
JRCSF binding to PG9/PGT145 class of antibodies is 
dependent on entire V2 domain
It has been previously demonstrated that JRFL, in con-
trast to JRCSF, binds weakly to PG9 and PG16 antibodies 
when expressed on the cell surface [3]. In this report, we 
have confirmed that JRCSF binds potently to PG9 and 
PG16 while JRFL binds poorly to those antibodies. We 
have also shown that JRCSF binds strongly to PGT145 
but not JRFL suggesting that JRCSF, in contrast to JRFL, 
has the advantage of the ability to bind to this class of 
bNAbs. Furthermore, the report by Walker et al. [3] has 
Fig. 1 Differential binding of JRFL and JRCSF to CD4-bs-directed bNAbs b12 and VRC01. FACS-based cell surface staining assay was used to meas-
ure binding of a glycan-dependent antibody 2G12, b, c CD4-bs-directed bNAbs b12 and VRC01, and d, e CD4-bs-directed non-NAbs F105 and b6 
to JRFL and JRCSF over a range of antibody concentration
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suggested that the conformational antibodies directed to 
the V2 and V3 variable loops and to a lesser extent co-
receptor directed antibodies compete with PG9 for gp120 
binding in ELISA and amino acid residues located in the 
conserved regions of the V2 and V3 loops play an impor-
tant role in antibody mediated neutralization assays of 
pseudotyped viruses. Asparagines, N156 and N160 were 
particularly critical for recognition by PG9 and PG16 
antibodies [3]. Besides JRFL, which is resistant to PG9 
and PG16, was rendered sensitive to these antibodies by 
an E168K mutation in the V2 loop [3]. So we compared 
JRFL (E168K) with JRCSF for their ability to bind PG9 
and PGT145 in FACS based cell surface binding assay 
(Fig. 3). Although JRFL (E168K) showed increased bind-
ing to PG9 and PGT145 as compared to JRFL it was not 
as efficient as JRCSF (Fig.  3, left and right panel) in its 
binding capability suggesting that JRCSF is a better Env 
than JRFL (E168K) with regards to its ability to efficiently 
bind this class of bNAbs.
In order to determine the minimal region in JRCSF, 
which imparts an advantage over JRFL in its ability 
to bind the PG9/PGT145 class of antibodies we used 
domain swapped mutants of JRCSF (Fig.  4a) in FACS 
based cell surface binding assays with PG9 and PGT145 
(Fig.  4c). The mutant V1*C2 where the V1 and C2 
domains of JRFL has been swapped into JRCSF binds 
efficiently to PG9 and PGT145 (Fig. 4c) while the mutant 
V2*C2 containing the V2 and C2 domains of JRFL 
swapped into JRCSF binds weakly to PG9 and PGT145 
(Fig.  4c), suggesting that the V2 domain of JRCSF is 
critical for its ability to bind to this class of antibodies. 
We next determined the amino acid residues in the V2 
domain of JRCSF that are critical for its ability to bind to 
this class of antibodies by replacing them with variants in 
JRFL. There are four amino acid changes between JRCSF 
and JRFL (K163T, N167D, K168E, and K191S) and one 
amino acid deletion (K187del) in the V2 domain (Fig. 4b). 
Two of these mutations viz N167D and K168E are in 
Fig. 2 FACS-based cell surface staining assay of JRFL and JRCSF with a–e the neutralizing Abs 2G12, PGT151, VRC34, PGT121, PGT145 and 10E8 and 
f–h non-neutralizing Abs, 39F, 17b and A32 over a range of antibody concentrations
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the strand C of V2 domain which plays a critical role in 
the ability of Envs to bind V1V2-directed bNAbs [39]. It 
should be noted here that Asparagines N156 and N160 
are conserved between JRCSF and JRFL. The mutants 
were subjected to FACS based cell surface staining assay 
with PG9 and PGT145 antibodies (Fig. 4d). None of the 
mutants showed a defect in binding to PG9 and PGT145 
as compared to JRCSF while JRFL showed weak binding 
as expected (Fig. 4d, left and right panel). JRCSF (K168E) 
was as efficient as JRCSF in its ability to bind PG9 and 
PGT145 (Fig. 4d). These results suggest that the entire V2 
domain of JRCSF is required for binding to PG9/PGT145 
class of antibodies.
Restoration of CD4‑bs‑directed antibody binding activity 
in JRCSF
Cell surface expressed JRCSF binds weakly to CD4-bs-
directed neutralizing antibodies (Fig.  1) as compared to 
JRFL. In order to use JRCSF for genetic vaccination and 
as a platform for immunogen design it is important that 
cell surface-expressed JRCSF binds efficiently to this cat-
egory of neutralizing antibodies. It has been reported 
previously, using pseudovirus neutralization assay that 
swapping the C2 domain of JRCSF with that from JRFL 
results in efficient neutralization of JRCSF pseudovi-
ruses by CD4-bs-directed antibodies [32]. Furthermore, 
Asn197 of JRCSF when mutated to Asp (N197D) restores 
ability of JRCSF to bind to CD4bs-directed antibodies in 
pseudovirus neutralization assay [32]. Asn197 may cause 
steric hindrance through the “umbrella effect” where a 
single glycan shields a local patch [40]. In order to inves-
tigate the minimal changes required to render JRCSF sen-
sitive to CD4-bs-directed antibodies when expressed on 
the cell surface we generated a series of domain swapped 
mutants of JRCSF where different domains of JRFL were 
swapped into JRCSF as shown in Fig. 5a and tested these 
mutants in FACS based cell surface binding assays. We 
found that JRFL gp120 domain swapped into JRCSF 
(gp120SW) bound efficiently to the CD4-bs-directed 
antibody, VRC01 but not gp41SW (gp41 domain of JRFL 
swapped into JRCSF) (Fig.  5b). The efficiency of bind-
ing of JRCSF (gp120SW) to VRC01 was much higher as 
compared to even JRFL Env. We then tested the mutants 
V1V2C2 (V1, V2 and C2 domains of JRFL swapped into 
JRCSF), V1V2 (V1 and V2 domains of JRFL swapped into 
JRCSF), V1*C2 (V1 and C2 domains of JRFL swapped 
into JRCSF), and V2*C2 (V2 and C2 domains of JRFL 
swapped into JRCSF) along with JRFL and JRCSF for 
their ability to bind to 2G12 and b12 (Fig.  5c). All the 
wild-type and mutant Envs bound to 2G12 to a similar 
extent suggesting that the wild type and all Env variants 
were expressed on the cell surface to a similar extent 
(Fig. 5c, left panel). The mutants V1V2C2, V1*C2, V2*C2 
but not V1V2 bound efficiently to b12 (Fig.  5c, right 
panel). The mutants V1V2C2 and V2*C2 showed higher 
binding to b12 than JRFL. We further tested the abil-
ity of these mutants along with wild-type Envs to bind 
to VRC01 and the non-neutralizing CD4-bs-directed 
antibody F105 (Fig.  5d). The mutants V1V2C2, V1*C2, 
V2*C2, bind efficiently to VRC01 but weakly to F105 
Fig. 3 Comparative binding of JRFL, JRCSF and JRFL (E168K) to V2 “cap” targeted glycan and conformation-dependent Abs PG9 and PGT145 over a 
range of antibody concentrations by FACS-based cell surface staining assay. The bar diagram represents the binding of the respective antibodies to 
wild type and mutant Envs at 20 µg/ml of antibody concentration
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(Fig. 5d). The binding of V1V2C2 and V2*C2 to VRC01 
was found to be higher than that of JRFL. This suggests 
that the difference in binding to CD4-bs-directed bNAbs 
between JRFL and JRCSF is attributed primarily to the C2 
domain of Env and is not due to a global disruption of the 
CD4-bs as there is no difference in binding to CD4-bs-
directed non-NAbs like F105 between the wild-type and 
mutant Envs.
Fig. 4 The entire V2 region of JRCSF is the primary determinant of JRCSF specificity towards PG9/PGT145 class of bNAbs. a Schematic represen-
tation showing swapping mutants of JRFL domains in JRCSF used in this experiment. b Sequence analysis of V2 domain of JRFL and JRCSF and 
position of mutants used in this experiment. c FACS-based cell surface staining assay of JRFL, JRCSF and the domain swapped mutants V1*C2 and 
V2*C2 with PG9 and PGT145 over a range of antibody concentrations. d Comparative binding of V2 domain mutants of JRCSF in a FACS-based cell 
surface assay with PG9 and PGT145 over a range of antibody concentrations. The bar diagram represents the binding of the respective antibodies to 
the wild type and different mutant Envs at 20 µg/ml of antibody concentration
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In order to further demonstrate that the C2 domain 
of JRFL restored the ability of JRCSF to bind to CD4-
bs-directed antibodies we tested the mutant C2 (JRFL 
C2 swapped into JRCSF) for its ability to bind b12 in 
the cell surface staining assay (Fig. 6a, right panel). We 
used binding to 2G12 as an expression control (Fig. 6a, 
left panel). The mutant C2 bound b12 better than JRFL 
itself (Fig. 6a, right panel) suggesting that swapping the 
C2 domain of JRFL into JRCSF restores the ability of this 
hybrid Env to bind to CD4-bs-directed bNAbs efficiently. 
We observed that the C2 region of JRCSF contains three 
N-linked glycosylation sites at position 197, 230 and 289 
which are absent in JRFL. Furthermore, in pseudovi-
rus neutralization assays it has been shown that muta-
tion of Asn197 of JRCSF to Asp causes JRCSF (N197D) 
pseudotyped viruses to be efficiently neutralized by 
b12 and VRC01 [32] suggesting that glycosylation at 
Asn may play a critical role in the differential binding 
of JRFL and JRCSF to CD4-bs-directed bNAbs. Con-
sequently, we mutated all three Asn residues at posi-
tion 197, 230 and 289 to their counterparts in JRFL and 
tested these mutants for their ability to bind to b12 and 
2G12 (Fig. 6a). The mutant JRCSF (N197D) is expressed 
to a similar extent as JRFL and JRCSF (Fig. 6, left panel) 
but binds more efficiently to b12 than JRFL (Fig. 6, right 
panel), comparable to the C2 mutant of JRCSF while the 
other two Asn mutants had no effect. Similarly, JRCSF 
(N197D) binds more efficiently to VRC01 than JRFL 
in cell surface binding assays (Fig.  6b). Taken together 
these studies demonstrate that mutating a single Asn 
at position 197 of JRCSF to Asp causes this mutant to 
bind to CD4-bs-directed bNAbs, b12 and VRC01 more 
Fig. 5 Domain swapping experiments to determine minimal region of JRFL, which confers CD4-bs-directed bNAb binding on JRCSF. a Schematic 
representation of domain swapped mutants. b–d FACS-based cell surface staining assay of JRFL, JRCSF and domain swapped mutants with the 
neutralizing Abs 2G12, VRC01, b12 and the non-neutralizing Ab F105 over a range of antibody concentrations
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efficiently than JRFL in cell surface staining assays and 
that this simple modification is sufficient to restore effi-
cient binding of JRCSF to the CD4-bs targeted bNAbs. 
Asn197 in BG505 and X1193.c1 in their crystal structure 
with PGT122-35022 and VRC01 is glycosylated and can 
sterically inhibit by the “umbrella effect” [40].
Restoration of CD4‑bs in JRCSF does not disrupt overall 
conformation
It has been previously reported that loss of the glycan 
at Asn197 of Env can affect its conformation [41] and 
allow CD4-independent entry and expose CD4-induced 
epitopes [42]. Here, we have shown that mutation of 
N197 in JRCSF to Asp not only restores binding to the 
CD4-bs antibodies but also increases its efficiency. We 
checked the binding to glycan and quaternary epitope-
dependent bNAbs PG9 and PGT128 to N197D mutated 
JRCSF in comparison to JRFL and wild-type JRCSF 
(Fig.  7). In addition, we determined whether the CD4-
induced epitopes get exposed in JRCSF (N197D) by 
studying its binding to the antibodies 17b and 412d in 
comparison to JRFL and wild-type JRCSF (Fig.  7). As 
shown in Fig.  7, JRCSF (N197D) binds efficiently to 
PG9 and PGT128 similar to wild-type JRCSF but poorly 
to the antibodies 17b and 412d. Taken together, these 
results suggest that JRCSF (N197D) maintains the native 
conformation.
JRCSF is efficiently cleaved on the cell surface
Naturally occurring, efficiently cleaved Envs like JRFL 
and 4-2.J41 when expressed on the cell surface bind 
preferentially to neutralizing antibodies over non-neu-
tralizing antibodies [23, 24]. Since JRCSF appears to 
specifically display neutralizing epitopes, we, therefore, 
sought to find out whether like JRFL Env, JRCSF is effi-
ciently cleaved on the cell surface. It has been demon-
strated earlier that the conformation of efficiently cleaved 
Env is different from uncleaved Env as the latter binds 
to both neutralizing and non-neutralizing antibod-
ies. We observed that JRCSF Env does not bind to non-
neutralizing antibodies on cell surface and this is due to 
the efficient cleavage of JRCSF Env on cell surface. An 
alternative explanation could be that the epitopes for the 
non-neutralizing antibodies are not present in this Env. It 
has been previously demonstrated with other efficiently 
cleaved Envs, JRFL and 4-2.J41 that mutating the cleavage 
site, REKR of gp160 to SEKS results in cleavage-deficient 
Env and the uncleaved Env binds to non-neutralizing 
antibodies [23, 33]. In order to check for the presence 
of epitopes for non-neutralizing antibodies in JRCSF 
Env, we first mutated the cleavage site, REKR of JRCSF 
to SEKS and then used FACS-based cell surface staining 
assay to compare both wild type and the mutant Env for 
their ability to bind to non-neutralizing antibodies F105, 
b6 and 39F when expressed on the cell surface (Fig.  8). 
Fig. 6 N197D mutation in JRCSF restores CD4-bs-directed bNAb binding to JRCSF. a FACS-based cell surface staining assay of JRFL, JRCSF and the 
mutants C2, N197D, N230D, N289K (all in JRCSF) with 2G12 and b12 over a range of antibody concentrations. b FACS-based cell surface assay of 
JRFL, JRCSF and the mutant JRCSF (N197D) with VRC01 over a range of antibody concentrations
Fig. 7 N197D mutant of JRCSF retains native conformation. FACS-based cell surface staining assay of JRFL, JRCSF and JRCSF (N197D) with glycan 
and quaternary epitope-dependent bNAbs PG9 and PGT128 and CD4i Abs 17b and 412d over a range of antibody concentrations
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We also used 2G12 and PGT121 antibodies to determine 
the relative expression levels of JRCSF and JRCSF (SEKS) 
mutants as controls (Fig.  8). Both JRCSF and JRCSF 
(SEKS) mutant bound to 2G12 and PGT121 to a simi-
lar extent suggesting that they are expressed to a similar 
extent on the cell surface (Fig. 8, top panel). Furthermore, 
in contrast to wild type JRCSF, JRCSF (SEKS) mutant 
bound to the non-neutralizing antibodies F105, b6 and 
39F with about twofold greater efficiency (Fig.  8, bot-
tom panel) suggesting that epitopes for non-neutralizing 
antibodies in efficiently cleaved JRCSF are present and 
they are occluded in its cleaved form on cell surface. The 
epitopes become exposed as a result of conformational 
change only when the Env is rendered cleavage defective.
We also tested JRCSF and JRCSF (SEKS) for their abil-
ity to bind to native, cleaved, trimer-targeted bNAbs 
PGT151 and PGT145. We have previously reported 
that JRFL (+) (cleavage-competent, tail-truncated 
JRFL) binds efficiently to PGT151 on the cell surface 
and this binding is considerably reduced upon mutat-
ing the gp160 cleavage site from REKR to SEKS [23]. As 
shown in Fig. 9a, both JRCSF and JRCSF (SEKS) bind to 
the glycan and quaternary epitope-dependent antibody, 
PG9 to a similar extent in cell surface antibody binding 
assay but JRCSF (SEKS) shows a twofold reduction in 
binding to PGT151 and a drastic reduction in binding 
to PGT145. This suggests that JRCSF, like JRFL, is pre-
sent in its native, trimeric, cleaved conformation on 
the cell surface. In addition, we used sCD4-mediated 
gp120-shedding to demonstrate that JRCSF is efficiently 
cleaved on the cell surface. Cell surface expressed, effi-
ciently cleaved Envs undergo conformational changes 
upon CD4 binding, which results in dissociation of the 
labile gp120-gp41 interaction and release of the gp120 
moiety [23, 33]. Following expression of JRCSF on the 
cell surface of transfected cells, incubation with sCD4 
was carried out and gp120 released into the supernatant 
in the absence and presence of sCD4 was measured by 
lectin mediated capture of Env followed by ELISA. Incu-
bation with sCD4 results in about a twofold increase in 
the amount of gp120 shed (Fig.  9b) in the supernatant 
demonstrating that JRCSF is efficiently cleaved on the 
cell surface.
We then used immunoprecipitation (IP) assay, as 
described in materials and methods section, to determine 
biochemically whether JRCSF is efficiently cleaved on the 
cell surface. As we observed an extra non-specific pro-
tein band migrating close to the expected protein band 
Fig. 8 Mutation of REKR cleavage sequence to SEKS in JRCSF exposes non-neutralizing epitopes. Comparative binding of JRCSF and JRCSF (SEKS) to 
neutralizing Abs 2G12 and PGT121 and non-neutralizing Abs F105, b6 and 39F over a range of antibody concentrations by FACS-based cell surface 
staining assay
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of molecular weight of gp120 while performing the IP 
assay of wild type JRCSF Env with cleavage-independent, 
glycan-directed antibody, 2G12 (data not shown), we 
performed immunoprecipitation of antigenically more 
relevant Env, JRCSF (N197D) with cleavage-independent, 
CD4-bs-directed antibody, VRC01 for determining its 
efficiency of cleavage on cell surface. Plasma membrane 
(PM) fractions of mock-transfected, JRFL and JRCSF 
(N197D) Env transfected cells were immunoprecipitated 
with cleavage non-specific bNAb VRC01 as indicated 
(Fig. 9c) and bound proteins subjected to SDS page fol-
lowed by western blot analysis. Both JRFL and JRCSF 
(N197D), immunoprecipitated with VRC01, shows a sin-
gle band migrating between the 100 and 150 kDa markers 
(Fig.  9c). JRFL has been previously reported to be effi-
ciently cleaved on the cell surface showing a single gp120 
band [24] suggesting that this single band in the JRFL 
and JRCSF lanes constitute the gp120 subunit. To verify 
whether the single band represents gp120 from cleaved 
Env, we compared the immunoprecipitated PM fraction 
of JRCSF (N197D) to the crude cell lysate of the clade B 
env, YU2 which has been shown to be uncleaved previ-
ously [24]. YU2 shows a single slower migrating band 
representing gp160 suggesting that the band in JRCSF 
(N197D) immunoprecipitated lane is gp120 (Fig.  9d). 
YU2 expression is relatively low (see Additional file  1: 
Figure  2 for higher exposure). Taken together our data 
provide strong evidence that JRCSF is efficiently cleaved 
on the cell surface.
Immunization with soluble versions of Env proteins is 
a viable option to elicit neutralizing antibodies. Towards 
that goal we tested the SOSIP version of JRCSFN197D 
(JRCSFN197DSOSIP) in crude supernatant of transfected 
293T cells (Additional file 2) for its ability to bind a panel 
of bNAbs (Additional file 1: Figure 3) by immunoprecipi-
tation (IP). We observed that in the absence of furin, a 
majority of JRCSFN197DSOSIP is in the cleaved form 
(gp120). Co-transfection with furin and IP with VRC01 
showed only gp120 band and co-migrated with bands 
obtained with other bNAbs, particularly the cleavage-
specific, trimer selective bNAbs PGT145 and PGT151. 
We also obtained interaction with non-NAb F105, sug-
gesting that like JRFLSOSIP [22], the JRCSFN197DSOSIP 
extract is a mixture of native-like Env trimers and non-
trimers. Thus, JRCSFN197DSOSIP displays the epitopes 
of all classes of bNAbs tested (except VRC34 which does 
not bind efficiently in cell surfaces staining assay). We 
intend to purify native-like trimers of JRCSFN197DSO-
SIP from this heterogenous pool using positive (PGT145) 
or negative (F105) selection and analyze its properties by 
biochemical, EM and biophysical studies.
Discussion
The currently available candidate vaccines generally lack 
the neutralization breadth [14, 15, 27, 43]. The diversity 
of HIV poses a major obstacle to developing a universally 
protective vaccine against HIV and prevention of AIDS. 
In order to contend with the diversity, there is a need to 
Fig. 9 Cleavage property of JRCSF Env. a Cell surface staining assay of JRCSF and JRCSFSEKS with PG9, PGT151 and PGT145 over a range of anti-
body concentrations. b ELISA assay of gp120 shedding of JRCSF transfected 293T cells incubated with and without 50 μg/ml sCD4-183. c Western 
blot analysis of VRC01 immunoprecipitates of plasma membrane fraction of JRFL and JRCSF(N197D) transfected 293T cell lysates with anti-clade B 
Env rabbit Abs. d Western blot analysis of VRC01 immunoprecipitate of plasma membrane fraction of JRCSF(N197D) transfected 293T cell lysates 
and crude lysate of YU2 with anti-clade B Env rabbit Abs
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isolate cleaved, trimeric, Envs in appropriate conformation 
from multiple clades for designing of polyvalent vaccine 
candidates. However, the search for such Envs has been 
confounded by the rarity of Envs that are naturally and 
efficiently cleaved, and the difficulty of obtaining soluble, 
metastable versions of Envs that display all the requisite 
properties desirable in immunogen candidates. Efficient 
cleavage of the Env gp160 polypeptide negatively correlates 
with its binding efficiency to non-neutralizing antibod-
ies but not to CD4-bs neutralizing antibodies. However, 
it positively correlates with glycan-directed conformation 
dependent broadly neutralizing antibodies and its ability 
to neutralize viruses pseudotyped with such Envs.
JRFL of clade B and the recently reported 4-2.J41 of 
clade C are the only known Envs, which are cleaved on 
the cell surface without requiring the co-expression of 
exogenous protease, furin. It is to be noted here that the 
efficiency of cleavage on cell surface may be screened by 
checking the binding ratio/stoichiometry between the 
CD4-bs directed neutralizing antibodies, b12 and/or 
VRC01 versus CD4-bs directed non-neutralizing anti-
bodies, F105 and/or b6 [23, 24]. Surprisingly, JRCSF Env 
does not bind efficiently to CD4-bs-directed antibod-
ies yet binds efficiently to cleavage dependent antibody, 
PGT151 suggesting that JRCSF does not exhibit the asso-
ciative property of binding to CD4-bs antibodies and 
cleavage. Furthermore, the cleavage efficiency was also 
proved by CD4-induced shedding and other biochemi-
cal data. Therefore, to broaden the repertoire of avail-
able Env immunogen candidates, it is desirable that more 
Envs with similar properties are identified.
In this study we show for the first time, that JRCSF is 
efficiently cleaved on the cell surface and that this prop-
erty of JRCSF correlates with its property to preferentially 
bind bNAbs when expressed on the cell surface, which 
is in agreement with previous reports of neutralization 
capacity of JRCSF pseudotyped viruses by bNAbs [34]. 
The fact that JRCSF presents itself on the cell surface in 
the correct, trimeric, native conformation makes it an 
ideal starting point to design immunogens aimed at elic-
iting neutralizing antibodies and also to design soluble 
variants of this Env similar to JRFL [22] and 4-2.J41 [23]. 
Also, JRCSF may be more “native-like” than JRFL in that 
it efficiently binds to PG9/PGT145 class of bNAbs even 
better than JRFL (E168K). The diversity of the variable 
regions 1 and 2 (V1/V2) of Env plays an important role 
to evade neutralizing antibody response. However, struc-
tural evidences have shown that N-linked glycosylation 
either clustered or dispersed along with strand-connect-
ing loops are involved in recognition of glycan-directed 
conformational antibodies [39, 40, 44] Although, N156 
and N160 in JRFL and JRCSF are conserved, there are 
some differences in strand C between these two Envs 
(Fig.  4b). However, single amino acid mutations in V2 
(N167D and K168E) did not abolish binding of JRCSF 
to V1V2 bNAbs. We do not rule out the possibility that 
the double mutant or other differences in the residues in 
the epitope for this class of bNAbs will have an effect on 
binding.
Furthermore, JRCSF, which binds weakly to CD4-bs-
directed antibodies, can be made to bind this class of 
bNAbs efficiently by incorporating the N197D mutation 
without disrupting its native conformation. It is to be 
noted here that the efficiency with which mutant JRCSF 
binds CD4-bs bNAbs is more than that of JRFL. Taken 
together our findings suggest that JRCSF can be added to 
the pool of efficiently cleaved, naturally occurring Envs 
that could be used to elicit neutralizing antibodies. The 
C2 dependent binding of CD4-bs-directed antibodies to 
JRCSF has been shown in virus context [32]. However, in 
the context of designing immunogens, it is important to 
determine whether JRCSF displays its properties when 
expressed either on cell surface or in its soluble form. 
Moreover, for the first time, we show the V2 dependent 
binding of broadly neutralizing antibodies to JRCSF on 
cell surface. In this study, we also demonstrate that JRCSF 
displays epitopes for newly isolated and relatively abun-
dant broadly neutralizing antibodies (except VRC34) that 
have been identified from HIV-1 infected individuals. 
Furthermore, its binding ability to CD4-bs antibodies can 
be enhanced by a simple modification without altering its 
binding ability to broadly neutralizing antibodies men-
tioned above.
Significant progress has also been made in generat-
ing soluble versions of Env proteins. Modified versions 
of JRFL, BG505, 16055 (clade C) and B41 (clade B) have 
been used to obtain metastable, purified proteins that 
display properties of improved immunogen candidates. 
We conclude that efficiently cleaved modified JRCSF Env 
would be a good starting point for designing an immuno-
gen with the goal of eliciting bNAbs, both as membrane 
bound form for the purpose of genetic vaccination as well 
as in its soluble form for protein boost, as it specifically 
displays nearly all the epitopes that bind to broadly neu-
tralizing antibodies. In this direction, we have generated 
JRCSFN197DSOSIP and shown that the crude soluble 
protein binds to a majority of tested bNAbs. In future, 
we intend to purify this protein and subject it to various 
biochemical, EM and biophysical assays in order to inves-
tigate its properties that are suitable for immunization 
studies in animal models.
Conclusion
Viral diversity is a significant impediment in developing 
a universal vaccine against HIV-1. It is likely that such a 
polyvalent vaccine will require that immunogens based 
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on the viral glycoprotein Env be developed from a wide 
variety of HIV-1 sub-types. However, currently avail-
able candidate immunogens have limited neutralization 
breadth and potency necessitating the search for newer 
Envs with desirable antigenic properties. Env-based 
immunogens, suitable for vaccination, can be delivered 
both by DNA-based methods as well as soluble pro-
teins. Here, we report the membrane bound properties 
of a clade B Env, JRCSF that is suitable for immunogen 
design. Cell surface expressed efficiently cleaved Envs 
are the closest mimic of native, trimeric forms of Env 
and co-relate with their ability to preferentially expose 
only broadly neutralizing epitopes. Previously, only two 
Envs, JRFL (clade B) and 4-2.J41 (clade C) were reported 
to be efficiently cleaved on the cell membrane. In this 
report, we show that JRCSF, another clade B Env, is effi-
ciently cleaved on the cell membrane and displays greater 
variety of broadly neutralizing epitopes as compared to 
JRFL, sometimes with superior binding efficiency and 
including quaternary and glycan-dependent epitopes. 
Our findings present evidences that JRCSF Env can be 
utilized as a suitable reagent for genetic vaccination as 
well as for designing soluble immunogens based on its 
efficient cleavage and superior antigenic profiles upon 
modification.
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